Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CODIAK BIOSCIENCES INC (CDAK) Stock Price & Overview
NASDAQ:CDAK • US1920101060
Current stock price
0.057 USD
-0.07 (-55.98%)
At close:
0.0399 USD
-0.02 (-30%)
After Hours:
The current stock price of CDAK is 0.057 USD. Today CDAK is down by -55.98%. In the past month the price decreased by -90.17%. In the past year, price decreased by -99%.
CDAK Key Statistics
52-Week Range0.0532 - 5.88
Current CDAK stock price positioned within its 52-week range.
1-Month Range0.0532 - 0.62
Current CDAK stock price positioned within its 1-month range.
- Market Cap
- 2.099M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.99
- Dividend Yield
- N/A
CDAK Stock Performance
Today
-55.98%
1 Week
-70.00%
1 Month
-90.17%
3 Months
-89.07%
Longer-term
6 Months -91.85%
1 Year -99.00%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
CDAK Stock Chart
CDAK Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CDAK. When comparing the yearly performance of all stocks, CDAK is a bad performer in the overall market: 99.86% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CDAK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDAK. Both the profitability and financial health of CDAK have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CDAK Earnings
Next Earnings DateMay 3, 2023
Last Earnings DateMar 15, 2023
PeriodQ3 / 2022
EPS Reported-$0.59
Revenue Reported
EPS Surprise 29.46%
Revenue Surprise -12.92%
CDAK Forecast & Estimates
7 analysts have analysed CDAK and the average price target is 9.18 USD. This implies a price increase of 16005.26% is expected in the next year compared to the current price of 0.057.
For the next year, analysts expect an EPS growth of 41.06% and a revenue growth 61.58% for CDAK
Analysts
Analysts82.86
Price Target9.18 (16005.26%)
EPS Next Y41.06%
Revenue Next Year61.58%
CDAK Financial Highlights
Over the last trailing twelve months CDAK reported a non-GAAP Earnings per Share(EPS) of -1.99. The EPS increased by 44.88% compared to the year before.
Income Statements
Revenue(TTM)34.07M
Net Income(TTM)-17.42M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.66 |
Chartmill High Growth Momentum
EPS Q2Q%39.18%
Sales Q2Q%-54.88%
EPS 1Y (TTM)44.88%
Revenue 1Y (TTM)101.86%
CDAK Ownership
Ownership
Inst Owners0%
Shares36.83M
Float24.35M
Ins Owners1.56%
Short Float %N/A
Short RatioN/A
CDAK Industry Overview
CDAK operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.8%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.1
CDAK Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CDAK
Company Profile
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
Company Info
IPO: 2020-10-14
CODIAK BIOSCIENCES INC
35 Cambridgepark Drive, Suite 500
Cambridge MASSACHUSETTS 02140 US
CEO: Douglas E. Williams
Employees: 102
Phone: 16179494100.0
CODIAK BIOSCIENCES INC / CDAK FAQ
What does CODIAK BIOSCIENCES INC do?
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
What is the current price of CDAK stock?
The current stock price of CDAK is 0.057 USD. The price decreased by -55.98% in the last trading session.
Does CDAK stock pay dividends?
CDAK does not pay a dividend.
How is the ChartMill rating for CODIAK BIOSCIENCES INC?
CDAK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CDAK stock?
CDAK stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for CODIAK BIOSCIENCES INC?
CODIAK BIOSCIENCES INC (CDAK) will report earnings on 2023-05-03.
Can you provide the ownership details for CDAK stock?
You can find the ownership structure of CODIAK BIOSCIENCES INC (CDAK) on the Ownership tab.